{"entity":{"id":"filo","kind":"company","name":"FILO (French Innovative Leukemia Organisation)","aka":["French Innovative Leukemia Organisation","FILO"],"tldr":"FILO is the French cooperative group for leukaemia trials, with its registered office in the haematology department of the Tours university hospital; in OnCo it leads a phase 2 trial of eltrombopag in older patients with acute myeloid leukaemia.","summary":"The French Innovative Leukemia Organisation (FILO) is a French leukaemia cooperative group whose registered office is at the CHU Bretonneau, Centre Henry Kaplan, cellular haematology department, 2 boulevard Tonnellé, Tours (filo-leucemie.org). No founding year is stated on the pages read. ClinicalTrials.gov names it lead sponsor (OTHER class, with Novartis as collaborator) of NCT03603795 (EPAG2015, phase 2, eltrombopag in elderly patients with acute myeloid leukaemia), the trial recorded in OnCo. It has no products of its own.","asOf":"2026-09-25","links":[{"label":"Official website","url":"https://www.filo-leucemie.org"},{"label":"ClinicalTrials.gov: trials led by French Innovative Leukemia Organisation","url":"https://clinicaltrials.gov/search?lead=French%20Innovative%20Leukemia%20Organisation"}],"tags":["ctgov-sponsor","cooperative-group"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct03603795"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo cooperative groups round (group websites, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-25"},"hq":"Tours","country":"FR","companyType":"cooperative-group","website":"https://www.filo-leucemie.org","investors":[],"funding":[]},"route":"/companies/filo/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"trial":[{"id":"nct03603795","kind":"trial","name":"Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy","route":"/trials/nct03603795/"}]}}